Skip to main content

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Recruiting · Phase 1, Phase 2 · NCT04176198

Conditions: Myelofibrosis

At a glance

Research payments reported, 2025
$2.6M
U.S. investigators named
29
Sites paid
39
Planned or actual enrollment
240

About the trial

Sponsor
Sumitomo Pharma America, Inc.
Tested
Nusivertib (drug), Ruxolitinib (drug), Momelotinib (drug)
Dates
Started 2019-12-16; completion 2030-04-30
Results posted
Not yet

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

From ClinicalTrials.gov, last updated 2026-10-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sumitomo Pharma America, Inc. reported $2.6M in research payments for this study in 2025 (9,274 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.